参考文献/References:
1 张智海, 张智若, 刘忠厚, 等. 中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究 [J]. 中国骨质疏松杂志, 2016, 22 (1): 1-8.
2 Hintze G, Graf D. [Osteoporosis] [J]. Med Monatsschr Pharm, 2016, 39(6): 228-234.
3 Ishtiaq S, Fogelman I, Hampson G. Treatment of post- menopausal osteoporosis: beyond bisphosphonates [J]. J Endocrinol Invest, 2015, 38(1): 13-29.
4 Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis [J]. BMJ, 2015, 351(4): h3783.
5 Chen L, Wang G, Zheng F, et al. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials [J]. Osteoporos Int, 2015, 26(9): 2355-2363.
6 Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo [J]. Science, 1969, 165(3899): 1262-1264.
7 Fleisch H, Russell RG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution [J]. Calcif Tissue Res, 1968, 2(1): Suppl:10-Suppl10a.
8 Reitsma PH, Teitelbaum SL, Bijvoet OL, et al. Differential action of the bisphosphonates (3- amino- 1- hydroxypropylidene)- 1,1- bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro [J]. J Clin Invest, 1982, 70(5): 927-933.
9 朱琳. 双膦酸盐类药物治疗骨质疏松的相对有效性及安全性评估 [J]. 中国现代医生, 2016, 54(7): 81-83, 86.
10 邢帅, 高延征, 高坤, 等. 双膦酸盐类药物治疗原发性骨质疏松症研究进展 [J]. 风湿病与关节炎, 2016, 5(3): 70-73.
11 葛菁, 冯雷, 刘燕, 等. 某院门诊药房 2013年-2014年抗骨质疏松类药物利用分析 [J]. 中国骨质疏松杂志, 2016, 22(4): 483-486.
12 Paskins Z, Warburton L. Bisphosphonates beyond five years [J]. BMJ, 2016, 352(期缺失): i264.
13 Abe Y, Iba K, Sasaki K, et al. Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice [J]. J Bone Miner Metab, 2015, 33(2): 125-134.
14 Kos M, Junka A, Smutnicka D, et al. Bisphosphonates enhance bacterial adhesion and biofilm formation on bone hydroxyapatite [J]. J Craniomaxillofac Surg, 2015, 43(6): 863-869.
15 Puljula E, Turhanen P, Vepsäläinen J, et al. Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters [J]. ACS Med Chem Lett, 2015, 6(4): 397-401.
16 Wang L, Guo TZ, Wei T, et al. Bisphosphonates inhibit pain, bone loss, and inflammation in a rat tibia fracture model of complex regional pain syndrome [J]. Anesth Analg, 2016, 123(4): 1033-1045.
17 Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid- induced osteoporosis. Glucocorticoid- Induced Osteoporosis Intervention Study Group [J]. N Engl J Med, 1998, 339(5): 292-299.
18 Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group [J]. Lancet, 1996, 348(941): 1535-1541.
19 Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group [J]. J Clin Endocrinol Metab, 2000, 85(11): 4118-4124.
20 Sakai A, Ito M, Tomomitsu T, et al. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus Calcium treatment in Japanese patients with primary osteoporosis [J]. Osteoporos Int, 2015, 26(3): 1193-1202.
21 Atabek ME, Pirgon O, Sert A. Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis [J]. J Pediatr Endocrinol Metab, 2006, 19(2): 169-172.
22 Muschitz C, Kocijan R, Pahr D, et al. Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis [J]. Calcif Tissue Int, 2015, 96(6): 477-489.
23 Inderjeeth CA, Glendenning P, Ratnagobal S, et al. Long- term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis [J]. Int J Womens Health, 2015, 7: 7-17.
24 Chesnut IH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J]. J Bone Miner Res, 2004, 19(8): 1241-1249.
25 Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate [J]. Osteoporos Int, 2016, 27(1): 1-12.
26 Feldbrin Z, Luckish A, Shargorodsky M. Effects of long- term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load [J]. Menopause, 2016, 23(1): 55-59.
27 Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group [J]. Osteoporos Int, 2000, 11(1): 83-91.
28 Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group [J]. JAMA, 1999, 282(14): 1344-1352.
29 Yu T, Witten PE, Huysseune A, et al. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model [J]. Dis Model Mech, 2016, 9(2): 155-163.
30 Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J]. N Engl J Med, 2007, 356(18): 1809-1822.
31 Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON- Pivotal Fracture Trial (PFT) [J]. J Bone Miner Res, 2012, 27(2): 243-254.
32 Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture [J]. N Engl J Med, 2007, 357(18): 1799-1809.
33 Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics [J]. Horm Res Paediatr, 2014, 82(5): 290-302.
34 Tian Y, Wang R, Liu L, et al. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report [J]. BMC Musculoskelet Disord, 2016, 17(1): 72.
35 范靖雪, 姜礼红, 孟佳, 等. 双膦酸盐的作用机制和急性时相反应 [J]. 中国骨质疏松杂志, 2016, 22(9): 1216-1220.
36 Blum L, Cummings K, Goulet JA, et al. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management [J]. Eur J Orthop Surg Traumatol, 2016, 26(4): 371-377.
37 Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications [J]. Ther Adv Chronic Dis, 2015, 6(4): 185-193.
38 Adler RA. Bisphosphonates and atypical femoral fractures [J]. Curr Opin Endocrinol Diabetes Obes, 2016, 23(6): 430-434.
39 Corrarino JE. Bisphosphonates and atypical stress fractures [J]. Reactions Weekly, 2009, 1243(1): 4-4.
40 Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
41 鲍云霞, 文春艳, 鲍艳霞, 等. 双膦酸盐致下颌骨坏死 1例 [J]. 人民军医, 2016, 59(1): 10.
42 许振起, 龙丽, 杨楠, 等. 双膦酸盐性颌骨坏死 8例临床分析 [J]. 山东医药, 2016, 56(2): 72-73.
43 魏斌, 孙国文. 双膦酸盐及其相关性颌骨坏死的机制和治疗 [J]. 国际口腔医学杂志, 2016, 43(4): 445-448.
44 Goldshtein I, Rouach V, Shamir-Stein N, et al. Role of side effects, physician involvement, and patient perception in Non- Adherence with oral bisphosphonates [J]. Adv Ther, 2016, 33(8): 1374-1384.
45 Bonomi M, Nortilli R, Molino A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis [J]. Med Oncol, 2010, 27(2): 224-229.
46 Reyes C, Hitz M, Prieto- Alhambra D, et al. Risks and benefits of bisphosphonate therapies [J]. J Cell Biochem, 2016, 117(1): 20-28.
47 Raje N, Vescio R, Montgomery CW, et al. Bone Marker- Directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the ZMARK study [J]. Clin Cancer Res, 2016, 22(6): 1378-1384.
48 李冬梅, 高克加. 不同双膦酸盐类药物在骨代谢的实验研究 [J]. 中国骨质疏松杂志, 2016, 22(3): 304-308.
49 Lee SH, Na WC, Park YK. Effect of intravenous administration of bisphosphonate for patients operatively treated for osteoporotic hip fracture [J]. Hip Pelvis, 2012, 24(2): 133-138.
50 Kim SC, Kim DH, Mogun H, et al. Impact of the U.S. food and drug administration’s Safety- Related announcements on the use of bisphosphonates after hip fracture [J]. J Bone Miner Res, 2016, 31 (8): 1536-1540.
51 Peng J, Liu Y, Chen L, et al. Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis [J]. Pak J Med Sci, 2016, 32(2): 499-504.
相似文献/References:
[1]邵明昊 吕飞舟 马晓生 夏新雷 王洪立 郑超君 张帆 姜建元.腰椎皮质骨钉道螺钉在骨质疏松症患者中
应用的三维有限元分析[J].中华老年骨科与康复电子杂志,2015,(02):1.[doi:10.3877/cma.j.issn.2096-0263.2015.02.001]
Shao Minghao,Lyu Feizhou,Ma Xiaosheng,et al.Biomechanical evaluation of lumbar pedicle screws using cortical bone trajectory in osteoporosis : a finite element study[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2015,(03):1.[doi:10.3877/cma.j.issn.2096-0263.2015.02.001]
[2]刘文宣 张宇宸 刘文聪 高霞 李涛 张晓琳.CTR 基因多态性与老年男性骨质疏松的相关性研究[J].中华老年骨科与康复电子杂志,2015,(02):19.[doi:10.3877/cma.j.issn.2096-0263.2015.02.004]
Liu
Wenxuan,Zhang Yuchen,Liu Wencong,et al.Association between calcitonin receptor gene polymorphism and osteoporosis in elderly men[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2015,(03):19.[doi:10.3877/cma.j.issn.2096-0263.2015.02.004]
[3]孙晗 杨惠林 孙佳佳 刘义杰 杨旭 孙思炜 周峰 孟斌.对比单双侧椎体后凸成形术治疗骨质疏
松性椎体压缩性骨折的Meta 分析[J].中华老年骨科与康复电子杂志,2015,(02):39.[doi:10.3877/cma.j.issn.2096-0263.2015.02 .008]
Sun Han,Yang Huilin,Sun Jiajia,et al.Unilateral versus bilateral percutaneous kyphoplasty in treating osteoporotic vertebral compression
fractures: A systematic review and meta-analysis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2015,(03):39.[doi:10.3877/cma.j.issn.2096-0263.2015.02 .008]
[4]赵德伟,马志杰,杨磊,等.多孔钽金属涂层髋关节假体置换治疗老年股骨颈骨折的临床疗效观察[J].中华老年骨科与康复电子杂志,2016,(02):92.[doi:10.3877/cma.j.issn.2096-0263.2016.02.006]
Zhao Dewei,Ma Zhijie,Yang Lei,et al.Clinical investigation of hip implants by using porous tantalum coating in the treatment of elderly femoral neck fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(03):92.[doi:10.3877/cma.j.issn.2096-0263.2016.02.006]
[5]宋会平,张柳.阿仑膦酸钠治疗老年女性严重骨质疏松症患者的疗效分析[J].中华老年骨科与康复电子杂志,2016,(03):141.[doi:10.3877/cma.j.issn.2096-0263.2016.03.003]
Song Huiping,Zhang Liu.Effcacy analysis of alendronate in the treatment of severe osteoporosis in senile women[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(03):141.[doi:10.3877/cma.j.issn.2096-0263.2016.03.003]
[6]石英,李宇,王洪伟,等.模型讲解与视频宣教对老年胸腰椎骨质疏松骨折经皮椎体后凸成形术护理的影响[J].中华老年骨科与康复电子杂志,2016,(03):146.[doi:10.3877/cma.j.issn.2096-0263.2016.03.004]
Shi Ying,Li Yu,Wang Hongwei,et al.Effect of explain through model and education through video on elderly patients with thoracolumbar osteoporotic fracture treated by percutaneous kyphoplasty[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(03):146.[doi:10.3877/cma.j.issn.2096-0263.2016.03.004]
[7]于沂阳,刘勃,陈伟,等.2008—2012 年河北医科大学第三医院老年骨折流行病学特征分析[J].中华老年骨科与康复电子杂志,2016,(03):172.[doi:10.3877/cma.j.issn.2096-0263.2016.03.009]
Yu Yiyang,Liu Bo,Chen Wei,et al.Epidemiological analysis of geratic fractures in the Third Affiliated Hospital to Hebei Medical University from 2008 to 2012[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(03):172.[doi:10.3877/cma.j.issn.2096-0263.2016.03.009]
[8]冯博,郝定均,郭浩.经皮椎体后凸成形术治疗老年骨质疏松性椎体压缩骨折的研究进展[J].中华老年骨科与康复电子杂志,2016,(03):185.[doi:10.3877/cma.j.issn.2096-0263.2016.03.012]
Feng Bo,Hao Dingjun,Guo Hao.Research progress of percutaneous kyphoplasty treatment on senile osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(03):185.[doi:10.3877/cma.j.issn.2096-0263.2016.03.012]
[9]侯建伟,谢仁国,李玉前,等.加长型 PFNA-Ⅱ和DHS治疗老年骨质疏松性股骨转子下骨折的疗效分析[J].中华老年骨科与康复电子杂志,2017,(01):22.[doi:10.3877/cma.j.issn.2096-0263.2017.01.005]
Hou Jianwei,Xie Renguo,Li Yuqian,et al.Clinical effective analysis of lengthened PFNA- II fixation and dynamic hip screw for senile osteoporotic subtrochanteric fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(03):22.[doi:10.3877/cma.j.issn.2096-0263.2017.01.005]
[10]王峰,雷涛,苗德超,等.经皮椎体成形术与经皮椎体后凸成形术治疗重度骨质疏松性椎体压缩骨折的疗效对比[J].中华老年骨科与康复电子杂志,2017,(03):143.[doi:10.3877/cma.j.issn.2096-0263.2017.03.003]
Wang Feng,Lei Tao,Miao Dechao,et al.Comparative analysis of percutaneous vertebroplasty and percutaneous kyphoplastyon for the elderly severe osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(03):143.[doi:10.3877/cma.j.issn.2096-0263.2017.03.003]